42
https://pubmed.ncbi.nlm.nih.gov/38094559
This observational study found that 24-week neoadjuvant denosumab therapy improved clinical symptoms and histological indicators in patients with giant cell tumors of the bone, with no significant difference between male and female participants, except for stromal cells.